Leadership & Pay ·
On September 8, 2026, TScan Therapeutics approved a retention program for key employees to support company operations
TCRXTScan Therapeutics, Inc.
On September 8, 2026, TScan Therapeutics approved a retention program for key employees to support company operations. CEO Gavin MacBeath will receive $822,000 in cash awards and 2,400,000 restricted stock units (RSUs), while Chief Legal and Strategy Officer Zoran Zdraveski will receive $416,000 in cash and 1,500,000 RSUs. Cash payments are split between November 2026/February 2027 and upon achievement of clinical milestones for the in vivo solid tumor program. Equity awards vest based on a financing milestone and subsequent anniversaries. TScan Therapeutics operates in the biotechnology industry, focusing on developing cancer immunotherapies.